Herein, to our knowledge, we present the first study of a multiplex gene expression biomarker panel in 147 patients with metastatic prostate cancer designed to detect three major mechanisms of resistance to ARSIs in prostate cancer: AR-Vs, AR pathway activation, and NEPC. The gene discussed is AR; the disease is metastatic prostate carcinoma.